Agenus

Yahoo Finance • 2 months ago

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults Wednesday, GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluat... Full story

Yahoo Finance • 4 months ago

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus In a regulatory filing Friday, Agenus Inc (NASDAQ:AGEN) revealed Bristol Myers Squibb & Co (NYSE:BMY) terminated a license, development, and commercialization agr... Full story

Yahoo Finance • 10 months ago

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy The study achieved durable elimination of ctDNA, a critical biom... Full story

Yahoo Finance • 11 months ago

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

growth curve Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport rock-bottom valuations right now. Wi... Full story

Yahoo Finance • last year

With 52% institutional ownership, Agenus Inc. (NASDAQ:AGEN) is a favorite amongst the big guns

Key Insights Significantly high institutional ownership implies Agenus' stock price is sensitive to their trading actions A total of 12 investors have a majority stake in the company with 51% ownership Analyst forecasts along with ownersh... Full story

Yahoo Finance • 2 years ago

Agenus to Provide Corporate Update and First Quarter 2023 Financial Report

Conference Call on Tuesday, May 9, 2023 at 8:30 a.m. ET LEXINGTON, Mass., April 25, 2023--(BUSINESS WIRE)--Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, t... Full story

Yahoo Finance • 2 years ago

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced th... Full story

Yahoo Finance • 2 years ago

Agenus (AGEN) Q4 2022 Earnings Call Transcript

Thank you for holding and welcome, everyone, to the Agenus fourth quarter and full year 2022 financial results conference call. This is a very extensive list of difficult-to-treat cancers that have been treated and failed prior treatments.... Full story

Yahoo Finance • 2 years ago

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives

Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer (MSS CRC), 50% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) and in seven additional metastatic, late-line cancers in... Full story

Yahoo Finance • 2 years ago

Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to prese... Full story

Yahoo Finance • 2 years ago

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior benefit compared to what has been reported for standard of care and other investigational... Full story

Yahoo Finance • 2 years ago

2 Momentum Trades Showing Worst to First Action

It seems every January a common theme emerges within my portfolio. Indeed, Real Money's Jonathan Heller creates and tracks a portfolio each year specifically based on this phenomenon. Let's start with small-cap biotech name Agenus Inc. , w... Full story

Yahoo Finance • 2 years ago

Agenus (NASDAQ:AGEN shareholders incur further losses as stock declines 12% this week, taking three-year losses to 42%

Many investors define successful investing as beating the market average over the long term. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret to report that long term Agenus Inc. (NASDAQ... Full story

Yahoo Finance • 2 years ago

Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI

LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the... Full story

Yahoo Finance • 2 years ago

Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference

LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr.... Full story

Yahoo Finance • 2 years ago

Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS-CRC and advanced... Full story

Yahoo Finance • 2 years ago

Agenus Provides Corporate Update and Third Quarter 2022 Financial Report

Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingInitiated Phase 2 ACTIVATE trials of botensilimab in adva... Full story

Yahoo Finance • 2 years ago

Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report

Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ET Company to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET to discuss with oncology experts clinical experience to date and expected development p... Full story

Yahoo Finance • 2 years ago

GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high vaccine efficacy observed in severe disease (94.1%), adults aged 70-79 years (93.8%) and... Full story

Yahoo Finance • 2 years ago

VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022 Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1) administration in frontline Glioblastoma (GBM)... Full story